Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. Show more

Location: 535 W 24th Street, New York, NY, 10011, United States | Website: https://www.neurogene.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

283.6M

52 Wk Range

$6.88 - $74.49

Previous Close

$19.87

Open

$19.91

Volume

56,844

Day Range

$19.30 - $19.91

Enterprise Value

22.49M

Cash

274.5M

Avg Qtr Burn

-18.32M

Insider Ownership

9.27%

Institutional Own.

-

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.